CSF3 and plasma cell myeloma: Recently reported phase III studies have also shown superiority of the combination of G-CSF with plerixafor over G-CSF alone for mobilizing PBPC in patients with non-Hodgkin lymphoma (NHL) and multiple myeloma (MM) [3, 4].